The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary cancer clinical trials research group dedicated to the treatment, prevention, and cure of adult malignancies. The Data Management Office (DMO) grant application requests funding to support the activities of the data management group. Under the direction of the Principal Investigator, Robert Gray, PhD, the ECOG DMO is responsible for data management, including providing efficient systems for data collection, monitoring timeliness of data submission, conducting central data review and processing, maintaining a central database, coordinating clinical review of data, and establishing quality control procedures to guarantee the accuracy of ECOG data. The DMO is also responsible for the education and training, including providing training for the Group membership in ECOG's policies and procedures, in use of the patient registration, adverse event reporting, and regulatory support systems, in proper data management procedures, and in use of the ECOG web site and other ECOG information systems and tools. This application requests funding for the period 05/01/2010 - 04/30/2016.
The primary goal of the ECOG Data Management Office is to conduct central data review and prepare high quality data for statistical analysis. The results of our trials benefit public health by improving the quality and standard of care for cancer patients.
|Adams, Sylvia; Gray, Robert J; Demaria, Sandra et al. (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-66|
|Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72|
|Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53|
|Kaplan, David; Sun, Zhuoxin; Tallman, Martin S et al. (2014) Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70. Cytometry A 85:798-808|
|Zeidan, Amer M; Lee, Ju-Whei; Prebet, Thomas et al. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol 167:62-8|
|Chung, C H; Lee, J W; Slebos, R J et al. (2014) A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 25:2230-6|
|Psyrri, Amanda; Lee, Ju-Whei; Pectasides, Eirini et al. (2014) Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res 20:3023-32|
|Schneider, B P; Li, L; Shen, F et al. (2014) Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 111:1241-8|
|Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8|
|Wilson, Melissa A; Zhao, Fengmin; Letrero, Richard et al. (2014) Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res 20:3328-37|
Showing the most recent 10 out of 220 publications